Inhalation Anesthesia Market, By Product (Sevoflurane, Desflurane, Isoflurane, and Nitrous Oxide), By Application (Induction and Maintenance), By End Users (Hospitals and Ambulatory Surgical Centers), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Published In : May 2023

Code : CMI2377

Pages :155

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global Inhalation Anesthesia Market: Key Developments

In August 2022, Piramal Critical Care launched the first to market Generic Zinc Sulfate Injection in the U.S. This product is U.S. Food and Drug Administration approved with Competitive Generic Therapy (CGT) designation; to enhance market competition for sole source drugs.

In January 2022, Dechra acquired Isoflurane and sevoflurane inhalant anesthetic products from Halocarbon Life Sciences. The 2 inhalation anesthesia solutions are used in both human and animal medicine. Dechra also planned to launch veterinary branded Isoflurane and Sevoflurane.

In June 2020, Piramal Critical Care signed a strategic partnership with US-based pharmaceutical outsourcing facility, Medivant Healthcare, to help address the severe shortage of injectable drugs in hospitals across the United States.

In April 2020, Blue-Zone Technologies Ltd. received a Drug Identification Number (DIN) from Health Canada for DESFLURANE, USP, an important drug used for general anesthesia. The DIN allows Blue-Zone to manufacture and market its branded generic medicine.